Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Shares Outstanding for 15 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 73.97% to $10.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.7 million, a 73.97% increase, with the full-year FY2025 number at $9.0 million, up 50.3% from a year prior.
  • Shares Outstanding was $10.7 million for Q4 2025 at Aytu Biopharma, up from $9.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $33.4 million in Q1 2022 to a low of $1.9 million in Q2 2022.
  • A 5-year average of $10.9 million and a median of $6.1 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: crashed 92.98% in 2022, then skyrocketed 186.02% in 2023.
  • Aytu Biopharma's Shares Outstanding stood at $30.0 million in 2021, then plummeted by 88.73% to $3.4 million in 2022, then skyrocketed by 64.56% to $5.6 million in 2023, then rose by 10.82% to $6.2 million in 2024, then soared by 73.97% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Shares Outstanding are $10.7 million (Q4 2025), $9.9 million (Q3 2025), and $9.0 million (Q2 2025).